1. Monash Health
  2. Monash Health research
  3. Articles
Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/36245
Full metadata record
DC FieldValueLanguage
dc.contributor.authorReagan J.L.en
dc.contributor.authorOlszewski A.J.en
dc.contributor.authorFedele P.en
dc.contributor.authorBibas M.en
dc.contributor.authorGrigoriadis G.en
dc.contributor.authorGilbertson M.en
dc.contributor.authorCastillo J.J.en
dc.contributor.authorGuerrero-Garcia T.en
dc.contributor.authorBaldini F.en
dc.contributor.authorTchernonog E.en
dc.contributor.authorCartron G.en
dc.contributor.authorNinkovic S.en
dc.contributor.authorCwynarski K.en
dc.contributor.authorDierickx D.en
dc.contributor.authorTousseyn T.en
dc.contributor.authorLansigan F.en
dc.contributor.authorLinnik Y.en
dc.contributor.authorMogollon R.en
dc.contributor.authorNavarro J.-T.en
dc.date.accessioned2021-05-14T12:17:15Zen
dc.date.available2021-05-14T12:17:15Zen
dc.date.copyright2019en
dc.date.created20190212en
dc.date.issued2019-02-12en
dc.identifier.citationBritish Journal of Haematology. 184 (4) (pp 679-682), 2019. Date of Publication: Februaryy 2019.en
dc.identifier.issn0007-1048en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/36245en
dc.languageenen
dc.publisherBlackwell Publishing Ltden
dc.relation.ispartofBritish Journal of Haematologyen
dc.titleBortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.en
dc.typeLetteren
dc.type.studyortrialOpinion, perspective or news-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/bjh.15156en
dc.publisher.placeUnited Kingdomen
dc.identifier.pubmedid29527667 [http://www.ncbi.nlm.nih.gov/pubmed/?term=29527667]en
dc.identifier.source621209118en
dc.identifier.institution(Castillo) Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States (Guerrero-Garcia) Division of Hematology and Oncology, Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Brighton, MA, United States (Baldini, Bibas) National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy (Tchernonog, Cartron) Department of Haematology, CHU Montpellier, Montpellier, France (Ninkovic, Cwynarski) Department of Haematology, UCLH London, London, United Kingdom (Dierickx, Tousseyn) Department of Haematology, University Hospitals Leuven, Leuven, Belgium (Lansigan, Linnik) Division of Hematology and Oncology, Dartmouth-Hitchcock Medical Center, Dartmouth Medical School, Lebanon, NH, United States (Mogollon) Department of Medicine, Universidad San Martin de Porres, Lima, Peru (Navarro) Catalan Institute of Oncology, German Trias I Pujol Hospital, Badalona, Spain (Olszewski, Reagan) Division of Hematology and Oncology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, United States (Fedele, Gilbertson, Grigoriadis) Monash Haematology, Monash Medical Centre, Monash University, Clayton, Australiaen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2019 Elsevier B.V., All rights reserved.en
dc.subect.keywordsbortezomib chemotherapy plasmablastic lymphoma survivalen
dc.identifier.authoremailCastillo J.J.; jorgej_castillo@dfci.harvard.eduen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeLetter-
crisitem.author.deptHaematology-
crisitem.author.deptHaematology-
crisitem.author.deptHaematology-
Appears in Collections:Articles
Show simple item record

Page view(s)

36
checked on Feb 6, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.